Document Detail

Tumor dormancy and cancer stem cells: two sides of the same coin?
MedLine Citation:
PMID:  23143979     Owner:  NLM     Status:  In-Data-Review    
Increasing evidence suggests that tumor dormancy represents an important mechanism underlying the observed failure of existing therapeutic modalities to fully eradicate cancers. In addition to its more established role in maintaining minimal residual disease after treatment, dormancy might also critically contribute to early stages of tumor development and the formation of clinically undetectable micrometastatic foci. There are striking parallels between the concept of tumor dormancy and the cancer stem cell (CSC) theory of tumor propagation. For instance, the CSC hypothesis similarly predicts that a subset of self-renewing cancer cells-that is CSCs-is responsible for tumor initiation, bears the preferential ability to survive tumor therapy, and persists long term to ultimately cause delayed cancer recurrence and metastatic progression. Additionally, many of the biological mechanisms involved in controlling the dormant state of a tumor can also govern CSC behavior, including cell cycle modifications, alteration of angiogenic processes, and modulation of antitumor immune responses. In fact, quiescence and immune escape are emerging hallmark features of at least some CSCs, indicating significant overlap between dormant cancer populations and CSCs. Herein, we crucially dissect whether CSCs occupy specific roles in orchestrating the switch between dormancy and exuberant tumor growth. We elucidate how recently uncovered CSC biological features could enable these cells to evade immunologic clearance and regulate cancer expansion, relapse, and progression. We propose that the study of CSC immunobiological pathways holds the promise to critically advance our understanding of the processes mediating tumor dormancy. Ultimately, such research endeavors could unravel novel therapeutic avenues that efficiently target both proliferating and dormant CSCs to minimize the risk of tumor recurrence in cancer patients.
Sonja Kleffel; Tobias Schatton
Related Documents :
24185179 - Pivotal role for ros activation of p38 mapk in the control of differentiation and tumor...
3808509 - In vitro growth characteristics and chemosensitivities of endometrial cancer using a so...
21193839 - A polymeric nanoparticle formulation of curcumin inhibits growth, clonogenicity and ste...
23715169 - A tissue-engineered gastric cancer model for mechanistic study of anti-tumor drugs.
21597289 - Beyond antiangiogenesis: intratumorally injected bevacizumab plays a cisplatin-sensitiz...
22207169 - Inhibition of matrine against gastric cancer cell line mnk45 growth and its anti-tumor ...
23036459 - Radiation therapy and immunotherapy: implications for a combined cancer treatment.
8640789 - Potential gastrointestinal tumor suppressor locus at the 3p14.2 fra3b site identified b...
20149229 - A mouse model for the sézary syndrome.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Advances in experimental medicine and biology     Volume:  734     ISSN:  0065-2598     ISO Abbreviation:  Adv. Exp. Med. Biol.     Publication Date:  2013  
Date Detail:
Created Date:  2012-11-12     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0121103     Medline TA:  Adv Exp Med Biol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  145-79     Citation Subset:  IM    
Harvard Skin Disease Research Center, Department of Dermatology, Brigham and Women's Hospital, Harvard Institutes of Medicine, Room 673B, 77 Avenue Louis Pasteur, Boston, MA, 02115, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Multifaceted kinetics of immuno-evasion from tumor dormancy.
Next Document:  Tumor dormancy: long-term survival in a hostile environment.